COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Robotic-assisted Left Hemicolectomy for Left Colon Cancer (RALH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03696472
Recruitment Status : Not yet recruiting
First Posted : October 4, 2018
Last Update Posted : October 9, 2018
Information provided by (Responsible Party):
Li Chuan, Southwest Hospital, China

Brief Summary:

The main goal of this study is to clarify if Robotic-assisted surgery could become the standard approach in patients undergoing left colonic resection.

Patient candidates to left colonic resection were randomly assigned to Robotic(RAL) or laparoscopic(LL) approach. The surgical staff who were not involved in the study registered 30-day postoperative morbidity. Cost-benefit analysis was based on hospital days. Long-term morbidity, quality of life, and 5-year survival have also been evaluated

Condition or disease Intervention/treatment Phase
Colon Cancer Procedure: robotic assisted surgery Procedure: laparoscopic Not Applicable

Detailed Description:
Robotic-assisted Left Hemicolectomy as advantages on showing the inferior mesenteric artery (IMA), protection of autonomic nerve compare to laparoscopic approach. Our experience found that operational flexibility was advantage without surgeon's position exchange.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Robotic-assisted Left Hemicolectomy for Left Colon Cancer With a Medial-to-lateral Approach Orientated by AMA or AMV
Estimated Study Start Date : December 2018
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: robotic-assisted left colonic resection
Standard left colonic resection assisted by Davinci Robotic
Procedure: robotic assisted surgery
robotic assisted surgery was benefit to operation

Active Comparator: laparoscopic left colonic resection
Standard laparoscopic left colonic resection
Procedure: laparoscopic
conventional laparoscopic surgery

Primary Outcome Measures :
  1. 5-years overall survival rate [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Short-term morbidity rate [ Time Frame: 30 days ]
  2. Anastomosis leakage rate [ Time Frame: 6 months ]
  3. Operation Time [ Time Frame: 1 day ]
  4. Blood loss during operation [ Time Frame: 1 day ]
  5. Complication incident rate of surgery [ Time Frame: 1 day ]
  6. C-reaction protein level [ Time Frame: 7 days ]
  7. Recovery time after surgery [ Time Frame: 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Colon cancer adenocarcinoma The tumor located between the descending colon and the right 1/3 of transverse colon Tumors T3,Т4а,b N0-2 Tolerance of chemotherapy ECOG 0-2

Exclusion Criteria:

With distant metastases Tumors T1-2 Complications of tumor Women during Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03696472

Layout table for location contacts
Contact: Li Chuan, M.D +862368754167
Contact: Tang Bo, M.D +86-18323479228

Layout table for location information
Southwest Hospital
Chongqing, China, 400038
Contact: Yu Peiwu, M.D/Ph.D    +862368754167   
Sponsors and Collaborators
Southwest Hospital, China
Layout table for additonal information
Responsible Party: Li Chuan, Secretary of General Surgery, Southwest Hospital, China Identifier: NCT03696472    
Other Study ID Numbers: RoboticALH
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases